Linagliptin is a Small Molecule owned by Boehringer Ingelheim International, and is involved in 85 clinical trials, of which 83 were completed, and 2 are ongoing.

Linagliptin acts as dipeptidyl peptidase-4 (DPP-4) inhibitor. The enzyme DPP-4 cleaves dipeptides from the N-terminal ends and interferes with the plasma level of bioactive peptides. Increase free fatty acid influx promotes liver inflammation. The drug candidate by inhibiting DPP-4 reduces the level of inflammatory cytokines such as TNF-alpha and interferon-gamma.

The revenue for Linagliptin is expected to reach a total of $1.7bn through 2032. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Linagliptin NPV Report.

Linagliptin is originated and owned by Boehringer Ingelheim International. Eli Lilly and Co is the other company associated in development or marketing of Linagliptin.

Linagliptin Overview

Linagliptin (Tradjenta, Trajenta, Ondero, Trayenta) is an anti-diabetic agent and anti-hyperglycemic agent. It is formulated as tablets and film coated tablets for oral route of administration. It is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control in adults.

Linagliptin is under development for the treatment of diabetic kidney disease (DKD). It was also under development for the treatment of non-alcoholic steatohepatitis (NASH).

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.

Quick View – Linagliptin

Report Segments
  • Innovator (NME)
Drug Name
  • Linagliptin
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.